[1]葛华,陈文新.桥本甲状腺炎合并甲状腺乳头状癌的特征及预后研究进展[J].国际放射医学核医学杂志,2017,41(6):443-447.[doi:10.3760/cma.j.issn.1673-4114.2017.06.011]
　Ge Hua,Chen Wenxin.Research progress of characteristics and prognosis for the Hashimoto’s thyroiditis coexistent with papillary thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):443-447.[doi:10.3760/cma.j.issn.1673-4114.2017.06.011]
点击复制

桥本甲状腺炎合并甲状腺乳头状癌的特征及预后研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第6期
页码:
443-447
栏目:
综述
出版日期:
2017-12-05

文章信息/Info

Title:
Research progress of characteristics and prognosis for the Hashimoto’s thyroiditis coexistent with papillary thyroid carcinoma
作者:
葛华;  陈文新
350001 福州, 福建医科大学省立临床医学院, 福建省立医院核医学科
Author(s):
Ge Hua;  Chen Wenxin
Provincial Clinic College of Fujian Medical University, Department of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou 350001, China
关键词:
桥本甲状腺炎; 甲状腺乳头状癌; 预后
Keywords:
Hashimoto’s thyroiditis; Papillary thyroid carcinoma; Prognosis
DOI:
10.3760/cma.j.issn.1673-4114.2017.06.011
摘要:
桥本甲状腺炎是一种常见的自身免疫性甲状腺疾病，甲状腺癌是常见的内分泌系统肿瘤，以甲状腺乳头状癌居多。近年来，桥本甲状腺炎合并甲状腺乳头状癌的报道越来越多，相关发病机制、预后情况也成为研究和争论的热点。笔者就桥本甲状腺炎合并甲状腺乳头状癌的流行病学、组织病理学特点、发病机制及预后的影响因素等研究进展做一综述。
Abstract:
Hashimoto’s thyroiditis is a common autoimmune thyroid disease, and thyroid carcinoma is the most common endocrine malignancy. Moreover, papillary thyroid carcinoma is the most prevalent manifestation in patients with thyroid carcinoma. Recently, the prevalence of Hashimoto’s thyroiditis coexisting with papillary thyroid carcinoma has increased, and the related pathogenesis and prognosis have become the focus of research and debate. This review focused on the research progress into epidemiological characteristics, histopathology features, pathogenesis, and prognosis-related factors of Hashimoto’s thyroiditis coexisting with papillary thyroid carcinoma.

参考文献/References:

[1] Anand A, Singh KR, Kushwaha JK, et al. Papillary thyroid cancer and hashimoto’s thyroiditis:an association less understood[J].Indian J Surg Oncol, 2014, 5(3):199-204. DOI:10.1007/s13193-014-0325-4.
[2] Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland[J]. AMA Arch Surg, 1955, 70(2):291-297.
[3] Zhang Y, Ma XP, Deng FS, et al. The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer[J]. World J Surg Oncol, 2014, 12:277. DOI:10.1186/1477-7819-12-277.
[4] Okayasu I, Fujiwara M, Hara Y, et al. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans[J]. Cancer, 1995, 76(11):2312-2318. DOI:10.1002/1097-0142(19951201)76:11<2312:AID-CNCR2820761120>3.0.CO; 2-H.
[5] Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited[J].World J Surg, 2001, 25(5):632-637. DOI:10.1007/s002680020165.
[6] Kim EY, Kim WG, Kim WB, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2009, 71(4):581-586. DOI:10.1111/j.1365-2265.2009.03537.x.
[7] Caturegli P, De Remigis A, Chuang K, et al. Hashimoto’s thyroiditis:celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records[J]. Thyroid, 2013, 23(2):142-150. DOI:10.1089/thy.2012.0554.
[8] Konturek A, Barczyński M, Nowak W, et al. Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto’s thyroiditis[J]. Langenbecks Arch Surg, 2014, 399(2):229-236. DOI:10.1007/s00423-013-1158-2.
[9] Lai X, Xia Y, Zhang B, et al. A meta-analysis of Hashimoto’s thyroiditis and papillary thyroid carcinoma risk[J]. Oncotarget, 2017, 8(37):62414-62424. DOI:10.18632/oncotarget.18620.
[10] Kim ES, Lim DJ, Baek KH, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules[J]. Thyroid, 2010, 20(8):885-891. DOI:10.1089/thy.2009.0384.
[11] Knobel M, Medeiros-Neto G. Relevance of Iodine intake as a reputed predisposing factor for thyroid cancer[J]. Arq Bras Endocrinol Metabol, 2007, 51(5):701-712. DOI:10.1590/S0004-273020070000500007.
[12] Mcleod DS, Watters KF, Carpenter AD, et al. Thyrotropin and thyroid cancer diagnosis:a systematic review and dose-response meta-analysis[J]. J Clin Endocrinol Metab, 2012, 97(8):2682-2692. DOI:10.1210/jc.2012-1083.
[13] Sadow PM, Heinrich MC, Corless CL, et al. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas[J]. Endocr Pathol, 2010, 21(2):73-79. DOI:10.1007/s12022-009-9101-3.
[14] Zhu F, Shen YB, Li FQ, et al. The effects of hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma a retrospective Chinese cohort study[J/OL]. Medicine (Baltimore), 2016, 95(6):e2674[2017-06-26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617515/. DOI:10.1097/MD.0000000000002674.
[15] Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis:a meta-analysis[J]. Eur J Endocrinol, 2013, 168(3):343-349. DOI:10.1530/EJE-12-0903.
[16] Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, et al. Association between Hashimoto’s thyroiditis and thyroid cancer in 64628 Patients[J/OL]. Front Oncol, 2017, 7:53[2017-06-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385456/. DOI:10.3389/fonc.2017.00053.
[17] Huang BY, Hseuh C, Chao TC, et al. Well-differentiated thyroid carcinoma with concomitant Hashimoto’s thyroiditis present with less aggressive clinical stage and low recurrence[J]. Endocr Pathol, 2011, 22(3):144-149. DOI:10.1007/s12022-011-9164-9.
[18] Ma B, Wang Y, Yang SW, et al. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma:A systematic review and meta-analysis[J]. Int J Surg, 2016, 28:153-161. DOI:10.1016/j.ijsu.2016.02.093.
[19] Singh B, Shaha AR, Trivedi H, et al. Coexistent hashimoto’s thyroiditis with papillary thyroid carcinoma:impact on presentation, management, and outcome[J]. Surgery, 1999, 126(6):1070-1076; discussion 1076-1077.
[20] Jeong JS, Kim HK, Lee CR, et al. Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma:clinical manifestation and prognostic outcome[J]. J Korean Med Sci, 2012, 27(8):883-889. DOI:10.3346/jkms.2012.27.8.883.
[21] Dobrinja C, Makovac P, Pastoricchio M, et al. Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome[J/OL]. Int J Surg, 2016, 28(S1):S70-74[2017-06-26]. https://linkinghub.elsevier.com/retrieve/pii/S1743-9191(15)01449-1. DOI:10.1016/j.ijsu.2015.12.059.
[22] Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer:initiators, amplifiers or an Achilles’ heel?[J]. Nat Rev Cancer, 2014, 14(11):709-721. DOI:10.1038/nrc3803.
[23] Loh KC, Greenspan FS, Dong F, et al. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 1999, 84(2):458-463. DOI:10.1210/jcem.84.2.5443.
[24] Bagnasco M, Venuti D, Paolieri F, et al. Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid:prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity[J]. J Clin Endocrinol Metab, 1989, 69(4):832-836. DOI:10.1210/jcem-69-4-832.
[25] Lucas SD, Karlssonparra A, Nilsson B, et al. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma[J]. Hum Pathol, 1996, 27(12):1329-1335. DOI:10.1016/S0046-8177(96)90346-9.
[26] Cunha LL, Ferreira RC, Marcello MA, et al. Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer[J/OL]. J Thyroid Res, 2011:387062[2017-06-26]. https://www.hindawi.com/journals/jtr/2011/387062/. DOI:10.4061/2011/387062.
[27] Li W, Ming H, Sun D, et al. The relationship between BRAFV600E, NF-κB and TgAb expression in papillary thyroid carcinoma[J].Pathol Res Pract, 2016, 213(3):183-188. DOI:10.1016/j.prp.2016.12.022.
[28] Giordano C, Stassi G, Demaria R, et al. Potential involvement of fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis[J]. Science, 1997, 275(532):960-963. DOI:10.1126/science. 275.5302. 960.
[29] Tano T, Okamoto M, Kan S, et al. Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma[J]. Neoplasia, 2013,15(3):305-314. DOI:10.1593/neo.121528.
[30] Pyzik A, Grywalska E, Matyjaszek-Matuszek B, et al. Immune disorders in hashimoto’s thyroiditis:what do we know so far?[J/OL]. J Immunol Res, 2015,(2015):979167[2017-06-26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426893/. DOI:10.1155/2015/979167.
[31] Zhang Q, Liu BJ, Ren WW, et al. Association between BRAFV600E mutation and ultrasound features in papillary thyroid carcinoma patients with and without Hashimoto’s thyroiditis[J]. Sci Rep, 2017, 7(1):4899. DOI:10.1038/s41598-017-05153-y.
[32] Pelizzo MR, Dobrinja C, Ide EC, et al. The role of BRAFV600E mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma[J]. Biomed Pharmacother, 2014, 68(4):413-417. DOI:10.1016/j.biopha.2014.03.008.
[33] Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment:a systematic review and meta-analysis[J]. Medicine (Baltimore), 2012, 91(5):274-286. DOI:10.1097/MD.0b013e31826a9c71.
[34] Kim SK, Woo JW, Lee JH, et al. Chronic lymphocytic thyroiditis and BRAFV600E in papillary thyroid carcinoma[J]. Endocr Relat Cancer, 2016, 23(1):27-34. DOI:10.1530/ERC-15-0408.
[35] Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J].Thyroid, 2009,19(2):137-141.DOI:10.1089/thy.2008.0144.
[36] Marotta V, Guerra A, Zatelli MC, et al. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto’s thyroiditis lymphocytic infiltration is present[J]. Clin Endocrinol (Oxf), 2013, 79(5):733-738.DOI:10.1111/cen.12194.

相似文献/References:

[1]冯思源,郑薇,张瑞国,等.甲状腺微小乳头状癌与乳头状非微小癌的临床特点及131I疗效的比较研究[J].国际放射医学核医学杂志,2018,(2):111.[doi:10.3760/cma.j.issn.1673-4114.2018.02.003]
　Feng Siyuan,Zheng Wei,Zhang Ruiguo,et al.Clinical characteristics and 131I efficacy of papillary thyroid microcarcinoma and papillary thyroid non-micro carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):111.[doi:10.3760/cma.j.issn.1673-4114.2018.02.003]

备注/Memo

备注/Memo:
收稿日期:2017-06-26。
通讯作者:陈文新,Email:wenxinchzt@aliyun.com
更新日期/Last Update: 2017-12-05